Want to see YARW full AI Analyst Report?
Top Page
Yarrow Bioscience
(NASDAQ:YARW)
Select Model
Select Model
Rating:57Neutral
Price Target:
$31.00
▲(2.62% Upside)
Action:Reiterated
Date:08/25/26
The score is held back primarily by weak financial performance (very small revenue relative to large ongoing losses and sustained negative free cash flow), despite a clean debt profile and high gross margins. Technicals are a key offset, with the stock trading above all major moving averages and supportive momentum readings. Valuation is mixed due to a negative P/E and an unusually high dividend yield that introduces uncertainty.
Positive Factors
Debt-Free Balance Sheet
Essentially no debt reduces fixed financial obligations and limits balance-sheet risk while the company funds clinical development. Positive equity provides some financial cushion, although continued losses mean this strength depends on improving operating performance and disciplined capital allocation.
Negative Factors
Severe Operating Losses
The company remains far from operating profitability: very small revenue is overwhelmed by research and development and other operating costs. This gap makes earnings highly dependent on successful clinical progress and future financing or partnering, rather than on an established self-funding commercial business.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Essentially no debt reduces fixed financial obligations and limits balance-sheet risk while the company funds clinical development. Positive equity provides some financial cushion, although continued losses mean this strength depends on improving operating performance and disciplined capital allocation.
Read all positive factors
Yarrow Bioscience (YARW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$80.65M
Dividend Yield66.53%
Average Volume (3M)33.92K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth1.26%
EPS Growth48.11%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.45
Shares Outstanding2,669,746
10 Day Avg. Volume54,284
30 Day Avg. Volume33,924
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$57.00Price Target Upside88.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-76
Revenue Forecast (FY)$350.00K
Yarrow Bioscience Business Overview & Revenue Model
Company Description
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormon...
How the Company Makes Money
As a clinical-stage company, VYNE Therapeutics does not have publicly disclosed, recurring product-sales revenue from commercialized drugs (null). Its cash inflows have primarily been driven by financing activities such as issuing equity and, wher...
Yarrow Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 482.00K | 570.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| Gross Profit | 470.00K | 547.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| EBITDA | -18.85M | -26.73M | -39.80M | -27.87M | -33.86M | -38.04M |
| Net Income | -18.71M | -26.48M | -39.83M | -28.45M | -23.21M | -73.33M |
Balance Sheet | ||||||
| Total Assets | 23.60M | 30.16M | 66.91M | 97.69M | 40.76M | 67.05M |
| Cash, Cash Equivalents and Short-Term Investments | 22.93M | 29.01M | 61.52M | 93.25M | 30.91M | 42.25M |
| Total Debt | 0.00 | 0.00 | 99.00K | 214.00K | 0.00 | 349.00K |
| Total Liabilities | 1.54M | 2.40M | 14.82M | 8.95M | 9.56M | 18.41M |
| Stockholders Equity | 22.06M | 27.77M | 52.09M | 88.73M | 31.20M | 48.64M |
Cash Flow | ||||||
| Free Cash Flow | -16.93M | -33.12M | -34.09M | -25.34M | -29.20M | -56.37M |
| Operating Cash Flow | -16.93M | -33.12M | -33.97M | -25.34M | -29.20M | -56.37M |
| Investing Cash Flow | 17.86M | 37.37M | 23.36M | -57.35M | 15.67M | 1.03M |
| Financing Cash Flow | -51.00K | -143.00K | -141.00K | 82.39M | 1.65M | 39.78M |
Yarrow Bioscience Technical Analysis
Neutral
30.21
Price Trends
29.15
Positive
23.78
Positive
19.38
Positive
Market Momentum
2.41
Positive
52.95
Neutral
34.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YARW, the sentiment is Neutral. The current price of 30.21 is below the 20-day moving average (MA) of 39.84, above the 50-day MA of 29.15, and above the 200-day MA of 19.38, indicating a neutral trend. The MACD of 2.41 indicates Positive momentum. The RSI at 52.95 is Neutral, neither overbought nor oversold. The STOCH value of 34.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for YARW.
Yarrow Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $80.65M | -1.29 | -70.23% | 70.38% | 1.26% | 48.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $10.94M | -3.92 | -40.62% | ― | 33.30% | 40.59% | |
46 Neutral | $11.83M | -0.64 | -91.18% | ― | ― | 81.87% | |
42 Neutral | $140.67M | -1.65 | -116.86% | ― | -98.25% | 76.83% | |
40 Underperform | $9.81M | >-0.01 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
YARW
Yarrow Bioscience
30.21
21.98
267.25%
KZIA
Kazia Therapeutics
12.31
4.21
51.98%
XBIO
Xenetic Biosciences
4.67
1.62
53.11%
KALA
KALA BIO
0.51
-723.49
-99.93%
INAB
IN8bio
1.20
-0.96
-44.44%
Yarrow Bioscience Corporate Events
Business Operations and Strategy
Yarrow Bioscience Alters Capital Structure With Warrant Exchange
Neutral
Jul 30, 2026
On July 29, 2026, Yarrow Bioscience, Inc. entered into an exchange agreement with an existing stockholder to swap 133,290 shares of common stock for an equal number of pre-funded warrants exercisable at a nominal price of $0.0001 per share. The pr...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesDividendsM&A TransactionsPrivate Placements and FinancingStock Split
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut
Positive
Jul 28, 2026
On July 27, 2026, Yarrow Bioscience closed its merger with VYNE Therapeutics, completed approximately $200 million in pre-closing private financings and began operating under the Yarrow Bioscience name, with shares trading on Nasdaq under the tick...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.